5-Chloro-2-[1-[2(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethyl]-piperidin-4-yl}-benzoic acid | 1000771-68-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 5-Chloro-2-[1-[2(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethyl]-piperidin-4-yl}-benzoic acid
• 英文别名: 5-chloro-2-[1-[2-(3-oxo-1,4-benzoxazin-4-yl)ethyl]piperidin-4-yl]benzoic acid
• CAS: 1000771-68-5
• 化学式: C₂₂H₂₃ClN₂O₄
• 分子量: 414.889
• InChiKey: DNNPUXXNPZHOTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-Chloro-2-[1-[2(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethyl]-piperidin-4-yl}-benzoic acid 、 4-N-(2-胺乙基)-1-N-BOC-哌啶 在 N-甲基吗啉 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 Tert-butyl 4-(2-(5-chloro-2-(1-(2-(3-oxo-2,3-dihydrobenzo[b][1,4]oxazin-4-yl)ethyl)piperidin-4-yl)benzamido)ethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: Synthesis, SAR, and in vivo assessment

  摘要：

  Various 4-phenylpiperidine-benzoxazin-3-ones were synthesized and biologically evaluated as urotensin-II (U-II) receptor antagonists. Compound 12i was identified from in vitro evaluation as a low nanomolar antagonist against both rat and human U-II receptors. This compound showed in vivo efficacy in reversing the ear-flush response induced by U-II in rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.092
• 作为产物：
  描述：

  5-Chloro-2-{1-{2-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethyl]-piperidin-4-yl}-benzoic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 5-Chloro-2-[1-[2(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-ethyl]-piperidin-4-yl}-benzoic acid
  参考文献：
  名称：

  Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: Synthesis, SAR, and in vivo assessment

  摘要：

  Various 4-phenylpiperidine-benzoxazin-3-ones were synthesized and biologically evaluated as urotensin-II (U-II) receptor antagonists. Compound 12i was identified from in vitro evaluation as a low nanomolar antagonist against both rat and human U-II receptors. This compound showed in vivo efficacy in reversing the ear-flush response induced by U-II in rats. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.092

文献信息

• Urotensin II receptor antagonists
  申请人：Ghosh Shyamali

  公开号：US20080039454A1

  公开（公告）日：2008-02-14

  The invention is directed to Urotensin II receptor antagonists. More specifically, the present invention relates to certain novel compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositions and methods for treating or ameliorating a Urotensin-II mediated disorder using compounds of the invention are also described.

  该发明涉及尿苷II受体拮抗剂。更具体地，本发明涉及某些新颖化合物以及制备这些化合物、组合物、中间体和衍生物的方法。还描述了使用本发明的化合物治疗或改善尿苷II介导的疾病的药物组合物和方法。
• Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists
  申请人：Shyamali Ghosh

  公开号：US08759342B2

  公开（公告）日：2014-06-24

  The invention is directed to benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one Urotensin II receptor antagonists useful in treating or ameliorating a Urotensin-II mediated disorder. More specifically, the present invention relates to certain novel benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositions and methods for treating or ameliorating a Urotensin-II mediated disorder using compounds of the invention are also described.

  本发明涉及苯并[1,4]噁嗪-3-酮，苯并[1,4]噻嗪-3-酮和喹啉-2-酮尿激肽II受体拮抗剂，用于治疗或改善尿激肽II介导的疾病。更具体地说，本发明涉及某些新型苯并[1,4]噁嗪-3-酮，苯并[1,4]噻嗪-3-酮和喹啉-2-酮化合物及其制备方法，组成物，中间体和衍生物。还描述了使用本发明化合物治疗或改善尿激肽II介导的疾病的药物组合物和方法。
• US8759342B2
  申请人：——

  公开号：US8759342B2

  公开（公告）日：2014-06-24
• [EN] UROTENSIN II RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'UROTENSINE II
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2008016534A1

  公开（公告）日：2008-02-07

  [EN] The invention is directed to Urotensin II receptor antagonists. More specifically, the present invention relates to certain novel compounds and methods for preparing compounds, compositions, intermediates and derivatives thereof. Pharmaceutical compositions and methods for treating or ameliorating a Urotensin-II mediated disorder using compounds of the invention are also described.
  [FR] L'objet de la présente invention concerne des antagonistes de récepteur d'Urotensine II. L'invention concerne de manière plus spécifique ceraines nouvelles méthodes et certains nouveaux composants destinés à préparer composants, compositions, produits intermédiaires et dérivés. Compositions pharmaceutiques et procédés pour traiter et améliorer un trouble induit par Urotensine II au moyen des composants est également l'objet de la présente invention.
• Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: Synthesis, SAR, and in vivo assessment
  作者：Diane K. Luci、Shyamali Ghosh、Charles E. Smith、Jenson Qi、Yuanping Wang、Barbara Haertlein、Tom J. Parry、Jian Li、Harold R. Almond、Lisa K. Minor、Bruce P. Damiano、William A. Kinney、Bruce E. Maryanoff、Edward C. Lawson

  DOI：10.1016/j.bmcl.2007.09.092

  日期：2007.12

  Various 4-phenylpiperidine-benzoxazin-3-ones were synthesized and biologically evaluated as urotensin-II (U-II) receptor antagonists. Compound 12i was identified from in vitro evaluation as a low nanomolar antagonist against both rat and human U-II receptors. This compound showed in vivo efficacy in reversing the ear-flush response induced by U-II in rats. (c) 2007 Elsevier Ltd. All rights reserved.